Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for the following three products from National Medical Products Administration of China, all being under type 4 chemical drug and regarded as passing the consistency evaluation.

1. Tropicamide Phenylephrine Eye Drops (0.4ml): This product is mainly used for pupil dilation and muscle relaxation in eyes for diagnosis and treatment purposes.

   Tropicamide Phenylephrine Eye Drop is a commonly used ophthalmic preparation for pupil dilation and refraction examinations, characterized by rapid onset and short duration of action, meeting a clear clinical need. This product is in 0.4ml single-dose packaging and preservative-free. It ensures a precise dosage for a single refraction test to minimize waste, and is better suited for pediatric refraction screening, enriching the Group's ophthalmic drug product line.

2. Tofacitinib Citrate Sustained-release Tablets (11mg): This product is mainly used for adult patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

   Tofacitinib is an oral small-molecule JAK inhibitor with overall clinical efficacy comparable to TNF-α inhibitor monoclonal antibodies. Compared to biologics requiring periodic injections, this product's sustained-release formulation allows for once-daily oral administration, bringing significant improvement in convenience and advantage in long-term patient adherence. The Group has its bulk pharmaceuticals production capacity, forming a layout of integration of "Bulk Pharmaceuticals + Preparations", ensuring cost control and stable supply. Such prominent product differentiation advantage makes it highly suitable for rheumatological and immunological chronic disease management scenarios, allowing a key layout of market channels such as dual-channel and outpatient retail to achieve long-term and steady market penetration.

3. Sacubitril Valsartan Sodium Tablets (200mg): This product is mainly used for adult patients with chronic heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.

   Sacubitril Valsartan Sodium Tablet is a first-line drug recommended by guidelines for heart failure and hypertension. This product delivers both antihypertensive effect and cardiovascular target organ protection effect, with proven clinical benefits, further enriching the Group's product portfolio in the field of cardiovascular and cerebrovascular chronic diseases.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 5 November 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.